Gary L. Johnson

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This paper uses mouse mammary tumor data to train machine learning models predicting human breast cancer survival and treatment response.

This study shows vandetanib enhances tamoxifen sensitivity in ER+ breast cancer by reprogramming ER gene regulation and kinase networks, identifying adaptive resistance pathways and response signatures.

This study shows trametinib causes mitochondrial injury and innate immune activation in mouse hearts, leading to cardiomyopathy and heart failure.

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

This study quantifies kinase protein abundance in human tissues using proteomic mass spectrometry, revealing heterogeneity in breast cancer subtypes and enabling clinical applications.

The paper predicts cancer cell line sensitivity to kinase inhibitor combinations using kinome inhibition states and machine learning, achieving high accuracy in both simulated and experimental settings.

The paper links kinome state with cell viability in PDAC tumor and stroma cell lines using regression and classification models, finding predictive relationships and key kinases driving viability responses.